bFGF and VEGF improve the quality of vitrified-thawed human ovarian tissues after xenotransplantation to SCID mice

Kang, Beijia; Wang, Yan; Zhang, Long; Xiao, Zhun; Li, Shangwei

doi:10.1007/s10815-015-0628-6

Cited by 48 publications

(25 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their results showed that these effects were ascribed to FGF2 alone but not VEGF (25–100 ng/mL) [37]. A recent study reported that preinjection of VEGF into the subcutaneous site of Nu mice and then grafting cryopreserved ovaries increased the number of follicles at each stage [38].…”

Section: Discussionmentioning

confidence: 99%

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

Hwu

et al. 2016

IJMS

View full text Add to dashboard Cite

This study was conducted to investigate the effect of the vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) on revascularization, survival, and oocyte quality of cryopreserved, subcutaneously-transplanted mouse ovarian tissue. Autologous subcutaneous transplantation of vitrified-thawed mouse ovarian tissues treated with (experimental group) or without (control group) VEGF and FGF2 was performed. After transplantation to the inguinal region for two or three weeks, graft survival, angiogenesis, follicle development, and oocyte quality were examined after gonadotropin administration. VEGF coupled with FGF2 (VEGF/FGF2) promoted revascularization and significantly increased the survival rate of subcutaneously-transplanted cryopreserved ovarian tissues compared with untreated controls. The two growth factors did not show long-term effects on the ovarian grafts. In contrast to the untreated ovarian grafts, active folliculogenesis was revealed as the number of follicles at various stages and of mature oocytes in antral follicles after gonadotropin administration were remarkably higher in the VEGF/FGF2-treated groups. Although the fertilization rate was similar between the VEGF/FGF2 and control groups, the oocyte quality was much better in the VEGF/FGF2-treated grafts as demonstrated by the higher ratio of blastocyst development. Introducing angiogenic factors, such as VEGF and FGF2, may be a promising strategy to improve revascularization, survival, and oocyte quality of cryopreserved, subcutaneously-transplanted mouse ovarian tissue.

show abstract

Section: Discussionmentioning

confidence: 99%

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

Hwu

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…One approach involves enhancement of graft revascularization by delivering both angiogenic and antiapoptotic factors, while others use antioxidants to decrease oxidative stress . Although some improvements have been seen in ovarian tissue outcomes, no clinically applicable protocol has yet had any discernible positive impact on follicle survival rates or graft vascularization.…”

Section: The Futurementioning

confidence: 99%

Recent advances in fertility preservation

Dolmans

Manavella

2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Background: Most cancer treatments like chemotherapy, radiotherapy or a combination of both are highly toxic to the gonads, putting girls and young women at risk of premature ovarian insufficiency and subsequent infertility. Non-oncological conditions may also require therapies that put women's reproductive potential at risk. Fertility preservation counseling should therefore be offered to all patients requiring gonadotoxic treatments, and to those who wish to postpone motherhood for social/personal reasons. Among the most effective fertility preservation options available today, oocyte and embryo cryopreservation, and ovarian tissue cryopreservation have emerged as the front-runners. Aim: This review focuses on the currently available and most widely accepted fertility preservation and restoration strategies, with a special focus on recent advances in ovarian tissue cryopreservation and transplantation. Conclusions: To manage cancer patients satisfactorily and offer proper counsel on the most appropriate option available to them, different parameters need to be taken into account, including pubertal status, partner status and urgency of treatment for the underlying pathology. When fertility preservation is carried out for non-oncological indications or personal reasons, oocyte cryopreservation by vitrification is clearly the highest-yield clinical strategy. Ovarian tissue cryopreservation followed by transplantation is rapidly gaining ground as a fertility preservation and restoration strategy, and will hopefully soon have its 'experimental' label removed to allow practitioners to move on to open clinical application. Techniques to improve grafted ovarian tissue life span and quality as well as to avoid transmission of malignant cells have been developed, showing promise as a way to expand this procedure.

show abstract

“…Several studies reported the positive effects of bFGF on angiogenesis and follicular survival in autograft and xenograft models, even though the total dose of bFGF (100–150 ng/mL for in vitro pretreatment, total 90–750 ng for in vivo administration via subcutaneous injection of free form or local transplantation with ovarian tissues using fibrin hydrogel or basement membrane extract) was much lower in these studies than in the present study (total 100 μg). However, it was not clear what was the actual dosage of active form of bFGF in vivo because there was no information about the in vivo release of bFGF.…”

Section: Discussionmentioning

confidence: 96%

“…Recently, various angiogenic growth factors have been evaluated for inducing neovascularization of fresh and frozen‐thawed ovarian grafts in autograft and xenograft animal models. Basic fibroblast growth factor (bFGF), which is one of the major regulators of angiogenesis, plays important roles not only in new vessel formation, but also in the modulation of vascular epithelial growth factor (VEGF) expression and upregulation of both FGF and VEGF receptors .…”

Section: Introductionmentioning

confidence: 99%

Effect of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogels on frozen‐thawed human ovarian tissue in a xenograft model

Tanaka

Nakamura

Tabata

et al. 2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

bFGF and VEGF improve the quality of vitrified-thawed human ovarian tissues after xenotransplantation to SCID mice

Abstract: The administration of bFGF alone or in combination with VEGF improved the quality of postgraft human ovarian tissue, though VEGF, regardless of different concentrations, did not influence effect of bFGF.

Cited by 48 publications

References 52 publications

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

VEGF and FGF2 Improve Revascularization, Survival, and Oocyte Quality of Cryopreserved, Subcutaneously-Transplanted Mouse Ovarian Tissues

Recent advances in fertility preservation

Effect of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogels on frozen‐thawed human ovarian tissue in a xenograft model

Contact Info

Product

Resources

About